Prevalence of PTPN11 and RAS gene mutations in the ALL and AML cohorts included in the study
. | PTPN11 . | . | NRAS and KRAS2 . | . | ||
|---|---|---|---|---|---|---|
| Malignancy . | No. of cases analyzed . | No. of cases with mutations (%)* . | No. of cases analyzed . | No. of cases with mutations (%)* . | ||
| ALL | ||||||
| Pro-B | 11 | 0 | 9 | 1 (11.1) | ||
| Common | 188 | 20§ (10.6) | 166 | 40 (24.1) | ||
| Pre-B | 113 | 3 (2.7) | 99 | 23 (23.2) | ||
| Pre-B/B | 5 | 0 | ||||
| T | 44 | 0 | 34 | 3 (8.8) | ||
| Not determined | 1 | 0 | ||||
| Total | 362 | 23 (6.3) | 308 | 67 (21.8) | ||
| P† | .019 | .114 | ||||
| AML‡ | ||||||
| M0 | 1 | 0 | 1 | 0 | ||
| M1 | 15 | 0 | 11 | 2 (18.2) | ||
| M2 | 18 | 0 | 12 | 2 (16.7) | ||
| M3 | 11 | 0 | 9 | 0 | ||
| M4 | 8 | 0 | 6 | 1 (16.7) | ||
| M5 | 12 | 4 (33.3) | 7 | 0 | ||
| M6 | 1 | 0 | 1 | 0 | ||
| M7 | 2 | 0 | 1 | 0 | ||
| Not determined | 1 | 0 | 1 | 0 | ||
| Total | 69 | 4 (5.8) | 49 | 5 (10.2) | ||
. | PTPN11 . | . | NRAS and KRAS2 . | . | ||
|---|---|---|---|---|---|---|
| Malignancy . | No. of cases analyzed . | No. of cases with mutations (%)* . | No. of cases analyzed . | No. of cases with mutations (%)* . | ||
| ALL | ||||||
| Pro-B | 11 | 0 | 9 | 1 (11.1) | ||
| Common | 188 | 20§ (10.6) | 166 | 40 (24.1) | ||
| Pre-B | 113 | 3 (2.7) | 99 | 23 (23.2) | ||
| Pre-B/B | 5 | 0 | ||||
| T | 44 | 0 | 34 | 3 (8.8) | ||
| Not determined | 1 | 0 | ||||
| Total | 362 | 23 (6.3) | 308 | 67 (21.8) | ||
| P† | .019 | .114 | ||||
| AML‡ | ||||||
| M0 | 1 | 0 | 1 | 0 | ||
| M1 | 15 | 0 | 11 | 2 (18.2) | ||
| M2 | 18 | 0 | 12 | 2 (16.7) | ||
| M3 | 11 | 0 | 9 | 0 | ||
| M4 | 8 | 0 | 6 | 1 (16.7) | ||
| M5 | 12 | 4 (33.3) | 7 | 0 | ||
| M6 | 1 | 0 | 1 | 0 | ||
| M7 | 2 | 0 | 1 | 0 | ||
| Not determined | 1 | 0 | 1 | 0 | ||
| Total | 69 | 4 (5.8) | 49 | 5 (10.2) | ||
Values refer to the prevalence of cases with PTPN11 or RAS gene mutations within each subtype and entire cohort.
Significance of the Fisher exact test for the independence of distributions of PTPN11 or RAS mutations across ALL immunophenotypes. The comparison of the distributions of PTPN11 and RAS mutations across B-cell precursors ALL immunophenotypes showed a statistically significant difference (P = .026, Fisher exact test).
AML patients were grouped according to the FAB classification.
One case showed mixed leukemic cell population expressing CD10+/CD33− (65% of cells) and CD10−/CD33+ (35% of cells).